Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 1
Submit an article Journal homepage
353
Views
17
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Mickaël Hiligsmann Department of Health Services Research, School for Public Health & Primary Care (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. [email protected]; Department of Internal Medicine, CAPHRI, Maastricht University, The Netherlands; Department of Clinical Epidemiology & Medical Technology Assessment, CAPHRI, Maastricht University, The Netherlands; Department of Health Services Research, School for Public Health & Primary Care (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. [email protected]; Department of Internal Medicine, CAPHRI, Maastricht University, The Netherlands; Department of Clinical Epidemiology & Medical Technology Assessment, CAPHRI, Maastricht University, The Netherlands
,
Annelies Boonen Department of Internal Medicine, CAPHRI, Maastricht University, The Netherlands; Department of Internal Medicine, CAPHRI, Maastricht University, The Netherlands
,
Carmen D Dirksen Department of Clinical Epidemiology & Medical Technology Assessment, CAPHRI, Maastricht University, The Netherlands; Department of Clinical Epidemiology & Medical Technology Assessment, CAPHRI, Maastricht University, The Netherlands
,
Wafa Ben Sedrine Department of Public Health, Epidemiology & Health Economics, University of Liège, Belgium; Department of Public Health, Epidemiology & Health Economics, University of Liège, Belgium
&
Jean-Yves Reginster Department of Public Health, Epidemiology & Health Economics, University of Liège, Belgium; Department of Public Health, Epidemiology & Health Economics, University of Liège, Belgium
Pages 19-28 | Published online: 09 Jan 2014

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Elisa Cairoli, Cristina Eller-Vainicher & Iacopo Chiodini. (2015) Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence. International Journal of Women's Health 7, pages 833-839.
Read now
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela & Mickael Lothgren. (2015) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. ClinicoEconomics and Outcomes Research 7, pages 105-117.
Read now
Kristel M Sidlauskas, Emily E Sutton & Michael A Biddle. (2014) Osteoporosis in men: epidemiology and treatment with denosumab. Clinical Interventions in Aging 9, pages 593-601.
Read now
Dima L Diab & Nelson B Watts. (2014) Denosumab in osteoporosis. Expert Opinion on Drug Safety 13:2, pages 247-253.
Read now

Articles from other publishers (13)

Y. Wan, F. Zeng, H. Tan, Y. Lu, Y. Zhang, L. Zhao & R. You. (2022) Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review. Osteoporosis International 33:5, pages 979-1015.
Crossref
Shijie Liao, Wenyu Feng, Yun Liu, Ziyi Wang, Xiaofei Ding, Fangming Song, Xixi Lin, Huijie Song, Anil KC, Yuangang Su, Jiamin Liang, Jiake Xu, Qian Liu & Jinmin Zhao. (2020) Inhibitory effects of biochanin A on titanium particle‐induced osteoclast activation and inflammatory bone resorption via NF‐κB and MAPK pathways. Journal of Cellular Physiology 236:2, pages 1432-1444.
Crossref
Hui Li, Jing Wang, Qiwen Sun, Gang Chen, Shengnan Sun, Xuemei Ma, Haiwen Qiu, Xuerong Liu, Liangyi Xu & Mei Liu. (2018) Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis. International Journal of Molecular Sciences 19:11, pages 3698.
Crossref
Paige Morizio, Jena I. Burkhart & Sachiko Ozawa. (2018) Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Annals of Pharmacotherapy 52:10, pages 1031-1041.
Crossref
C. Beaudoin, S. Jean, L. Bessette, L.-G. Ste-Marie, L. Moore & J. P. Brown. (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporosis International 27:9, pages 2835-2844.
Crossref
MINGJUN LI, WENGANG WANG, LI GENG, YANRU QIN, WENJIE DONG, XUDONG ZHANG, AN QIN & MINGZHI ZHANG. (2015) Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. International Journal of Molecular Medicine 36:5, pages 1335-1344.
Crossref
Shuai Chen, Gu Jin, Kang-Mao Huang, Jian-Jun Ma, Qiang Wang, Yan Ma, Xiao-Zhen Tang, Zhi-Jie Zhou, Zhi-Jun Hu, Ji-Ying Wang, An Qin & Shun-Wu Fan. (2015) Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo. Scientific Reports 5:1.
Crossref
Mickaël Hiligsmann, Silvia M. Evers, Wafa Ben Sedrine, John A. Kanis, Bram Ramaekers, Jean-Yves Reginster, Stuart Silverman, Caroline E. Wyers & Annelies Boonen. (2014) A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics 33:3, pages 205-224.
Crossref
Navdeep Dahiya, Anjan Khadka, A.K. Sharma, A.K. Gupta, Nishith Singh & D.B.S. Brashier. (2015) Denosumab: A bone antiresorptive drug. Medical Journal Armed Forces India 71:1, pages 71-75.
Crossref
Chuanlong Wu, Wengang Wang, Bo Tian, Xuqiang Liu, Xinhua Qu, Zanjing Zhai, Haowei Li, Fengxiang Liu, Qiming Fan, Tingting Tang, An Qin & Zhenan Zhu. (2015) Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro. Biochemical Pharmacology 93:1, pages 59-71.
Crossref
Cornelia Then, Emmo von Tresckow, Reiner Bartl & Fuat S. Oduncu. 2015. Medication-Related Osteonecrosis of the Jaws. Medication-Related Osteonecrosis of the Jaws 17 26 .
Antonio Cano, José Manuel Silvan, Antonio Estévez, Francesc Baró, José Villero, Francisco Quereda, Javier Ferrer, Nicolás Mendoza & Rafael Sánchez-Borrego. (2014) Spanish Menopause Society position statement: Use of denosumab in postmenopausal women. Maturitas 79:1, pages 117-121.
Crossref
Z J Zhai, H W Li, G W Liu, X H Qu, B Tian, W Yan, Z Lin, T T Tang, A Qin & K R Dai. (2014) Andrographolide suppresses RANKL ‐induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo . British Journal of Pharmacology 171:3, pages 663-675.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.